Q: What is a pharmaceutical regulatory gap analysis and what does it assess?
A: A regulatory gap analysis is a structured, systematic assessment comparing a company’s current regulatory posture against applicable regulations, agency guidelines, and best-practice expectations. It covers: pharmacovigilance systems; quality management; CMC documentation; labeling compliance; post-approval obligations; clinical trial compliance; and regulatory submission completeness. The output is a prioritized gap register with risk classifications (critical/major/minor) and a time-bound remediation roadmap. It is essential for pre-submission readiness, inspection preparation, and post-M&A integration.
Q: How does regulatory compliance consulting differ from general regulatory affairs consulting?
A: Regulatory affairs consulting covers the full spectrum of drug/device development and market access strategy — submissions, health authority interactions, lifecycle management. Regulatory compliance consulting is a focused discipline addressing whether ongoing operations, systems, documentation, and processes meet current regulatory requirements. Compliance consultants conduct audits, perform gap analyses, develop SOPs, design training programs, and support remediation — especially valuable post-inspection, during market expansion, or after regulatory changes such as new GVP or GMR updates.
Q: What does a pharmaceutical regulatory compliance audit typically cover?
A: A comprehensive regulatory compliance audit assesses: pharmacovigilance systems and PSMF accuracy; QMS effectiveness and CAPA performance; regulatory submission records and adherence to timelines; product labeling version control and accuracy; CMC change management and post-approval variations; GCP compliance for ongoing or completed clinical trials; supplier and vendor qualification records; data integrity systems and ALCOA+ adherence; regulatory intelligence processes; and overall inspection readiness posture. Findings are risk-rated and compiled in a formal audit report.
Q: What is regulatory intelligence (RI) and how does it support compliance?
A: Regulatory intelligence is the proactive, systematic monitoring and analysis of regulatory changes — new guidelines, consultation papers, agency communications, competitive approvals, and enforcement trends — across relevant markets. RI enables companies to: anticipate evolving requirements and update systems proactively; align global regulatory strategies with current agency thinking; brief senior management and boards on material regulatory risk; and reduce compliance gaps caused by reactive (rather than proactive) responses to change. RI is especially critical for companies operating in multiple jurisdictions.
Q: What is post-approval change management and what are the regulatory requirements?
A: Post-approval change management (PACM) governs how changes to approved pharmaceutical products (formulation, manufacturing, labeling, clinical use, site) are assessed, classified, and notified to or approved by health authorities. In the EU, changes are managed under the Variations Regulation (EC) No 1234/2008 — classified as Type IA, IB, or II based on risk. In the USA, FDA uses Prior Approval, CBE-30, CBE-0, and Annual Report categories under 21 CFR 314.70. ICH Q12 provides a global framework for lifecycle change management, including Established Conditions and Post-Approval Change Management Protocols.
Q: What are the most common triggers for initiating a regulatory compliance remediation programme?
A: Common triggers include: critical or major findings from a health authority inspection (FDA Warning Letter, EU GMP non-compliance notification); failed internal or external audit; significant regulatory change impacting existing systems (e.g., EU MDR transition, new GVP module); merger or acquisition requiring harmonization of two compliance systems; market expansion into a new jurisdiction with different regulatory requirements; or proactive risk identification during routine management review. Early engagement with an experienced regulatory consulting firm significantly improves remediation speed and effectiveness.
Comments are closed